Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2107)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (105)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (846)
  3. JNCI: Journal of the National Cancer Institute (485)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4652)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2-p53 antagonist BI 907828 in patients (pts) with solid tumours
    Meeting Abstract

    Schoeffski, P.; Yamamoto, N.; Bauer, T.; Patel, M.; Gounder, M. M.; Geng, J.; Sailer, R.; Jayadeva, G.; Lorusso, P.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • METEOR-1: A phase I study of the safety and efficacy of the protein arginine methyltransferase 5 (PRMT5) inhibitor GSK3326595 in advanced solid tumors
    Meeting Abstract

    Postel-Vinay, S.; Italiano, A.; Martin Romano, P.; Cassier, P. A.; Siu, L. L.; Lossos, I. S.; Hilton, J. F.; Mckean, M. A.; Strauss, J.; Falchook, G. S.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers
    Meeting Abstract

    Jhaveri, K.; Han, H.; Dotan, E.; Oh, D. Y.; Ferrario, C.; Tolcher, A.; Lee, K. W.; Liao, C. Y.; Kang, Y. K.; Kim, Y. H.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: Extended follow-up of a phase I/II study
    Meeting Abstract

    Doi, T.; Patel, M.; Falchook, G. S.; Koyama, T.; Friedman, C. F.; Piha-Paul, S.; Gutierrez, M. E.; Abdul-Karim, R.; Awad, M.; Adkins, D. R.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Pharmaceutical agents as potential drivers in development of early-onset colorectal cancer (EOCRC)
    Meeting Abstract

    Ben-Aharon, I.; Rotem, R.; Cercek, A.; Half, E.; Goshen-Lago, T. G.; Chodick, G.; Kelsen, D. P.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Tucatinib plus trastuzumab in patients (Pts) with HER2-positive metastatic colorectal cancer (mCRC): Patient-reported outcomes (PROs) from ph II study MOUNTAINEER
    Meeting Abstract

    Wu, C.; Strickler, J. H.; Cercek, A.; Siena, S.; AndreĢ, T.; Ng, K.; Van Cutsem, E.; Paulson, A. S.; Hubbard, J.; Coveler, A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • A phase Ia/b, open-label, multicentre study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers
    Meeting Abstract

    Harding, J. J.; Hofheinz, R. D.; Elez Fernandez, M. E.; Kuboki, Y.; Rasco, D.; Cecchini, M.; Shen, L.; Archuadze, S.; Geng, J.; Haderk, F.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Evaluation of regorafenib treatment PERSOnalization based on therapeutic drug monitoring in patients with metastatic colorectal cancer (mCRC): RePERSO study
    Meeting Abstract

    Tron, C.; Lemaitre, F.; Locher, C.; Lecomte, T.; Tournigand, C.; Bouhier Leporrier, K.; Le Sourd, S.; Metges, J. P.; Tougeron, D.; Di Fiore, F.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Tumor-infiltrating lymphocytes (TILs) in paired samples from patients with phenotypic switch from early luminal-like to metastatic triple-negative breast cancer
    Meeting Abstract

    Morganti, S.; Marra, A.; Venetis, K.; Sajjadi, E.; Ascione, L.; Corti, C.; Zagami, P.; Ivanova, M.; Zattoni, L.; Curigliano, G.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • ACE-Breast-03: A phase II study patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens treated with ARX788
    Meeting Abstract

    Hurvitz, S. A.; Kalinsky, K.; Tripathy, D.; Sledge, G.; Gradishar, W. J.; O'Shaughnessy, J.; Modi, S.; Park, H.; McCartney, A.; Frentzas, S.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save